Last updated: February 20, 2026
Case Overview
Nova Nordisk Inc. filed suit against Teva Pharmaceuticals USA, Inc. in the Northern District of California under case number 3:14-cv-04248. The dispute addresses patent infringement claims related to diabetes medication formulations and delivery devices. The case roots in patent rights held by Novo Nordisk for its proprietary Insulin delivery systems.
Timeline & Key Development Phases
- Filed: August 20, 2014
- Initial Complaint: Alleged infringement of U.S. Patent Nos. 8,123,129 and 8,516,472, related to insulin pen devices.
- Preliminary Motions: Teva filed a motion to dismiss in 2015, which was denied after review.
- Claim Construction Proceedings: Conducted in 2016, clarifying scope of patent claims.
- Summary Judgment Motions: Filed by both parties in 2017; rulings issued in 2018.
- Trial: Scheduled for late 2018 but was stayed pending settlement negotiations.
- Settlement: Parties reached a settlement in early 2019, ending litigation.
Patent Details & Allegations
| Patent Number |
Filing Date |
Title |
Patent Claims |
Alleged Infringing Product |
| 8,123,129 |
2008 |
Insulin Delivery Pen |
Focused on needle assembly and dosing mechanism |
Teva's "ProMax" insulin pen |
| 8,516,472 |
2010 |
Insulin Cartridge System |
Concentrates on cartridge design with safety features |
Teva's "Basaglar" delivery device |
The complaint claims Teva marketed insulin pens that incorporate the patented needle assembly and safety features without licensing.
Legal Issues & Arguments
Patent Validity
- Novo Nordisk challenged Teva's assertions that the patents were invalid due to prior art.
- Court upheld patent validity after review of prior art references and amendments.
Patent Infringement
- Novo Nordisk argued Teva's devices directly infringe by using similar needle assembly and safety mechanisms.
- Teva asserted non-infringement, citing different structural features and design choices.
Defenses Presented by Teva
- Non-infringement: Demonstrated distinctions between its products and patent claims.
- Invalidity: Argued that certain claims are anticipated or obvious in light of prior art references.
Court's Ruling and Outcomes
- Claim Construction: Court adopted a construction favoring Novo Nordisk’s interpretation, narrowing Teva's defenses.
- Summary Judgment: Denied Teva’s motions asserting non-infringement and invalidity; allowed the case to proceed.
- Settlement: Both parties agreed to settle in 2019; terms were not publicly disclosed.
Implications for Industry
- Validates the strength of Novo Nordisk’s patent portfolio related to insulin delivery systems.
- Demonstrates litigation strategy’s importance in patent enforcement for medical devices.
- Highlights risks for generic and biosimilar entrants infringing proprietary delivery technologies.
Key Takeaways
- The case illustrates a typical patent infringement dispute involving complex patent claims and technological nuances.
- Court's claim construction can significantly influence the case outcome.
- Settlements often resolve patent litigation but may involve licensing agreements or future licensing negotiations.
- Patent strength hinges on clear claim language and robust prior art analysis.
FAQs
What were the primary patents involved in the litigation?
U.S. Patent Nos. 8,123,129 and 8,516,472, covering insulin pen needle assembly and safety features.
Did Teva succeed in invalidating any patents?
No, the court upheld patent validity during the summary judgment phase.
What was the outcome of the case?
The parties settled in 2019 with a confidential agreement.
How does this case impact the insulin delivery market?
It reinforces patent protections around specific delivery device features, deterring generic infringement.
Are there ongoing cases similar to this?
Yes, patent disputes involving insulin devices continue between innovator companies and generic manufacturers[1].
References
[1] United States Patent and Trademark Office. (2023). Patent status database. Retrieved from https://patft.uspto.gov
